if AccessBio revenue all come in Q1, then AT1 get nothing from AccessBio from Q2 onwards. Unless we have other significant revenue channels, you would expect a smaller Q2 compare to Q1.
I think that's what danhoff saying...
AT1 FY21 - General Discussion + FA, page-1494
Add AT1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $13.42M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 11363 | 2.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.3¢ | 269439 | 3 |
View Market Depth
| Last trade - 09.59am 21/10/2024 (20 minute delay) ? |
| AT1 (ASX) Chart |
Day chart unavailable